Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

GSK’s HIV drug receives EU marketing nod

Written by: | no-reply@reuters.com | Dated: Wednesday, July 3rd, 2019

 

(Reuters) – GlaxoSmithKline said its specialist HIV company had received marketing authorization from the European Commission for its drug to treat advanced stage HIV infections in adults and adolescents above the age of 12 and weighing at least 40 kg.

ViiV Healthcare, which is majority owned by GSK and with Pfizer Inc and Shionogi Ltd as shareholders, got the U.S. Food and Drug Administration approval for the treatment Dovato in April.

 

Reporting by Noor Zainab Hussain in Bengaluru; editing by Gopakumar Warrier

 

Reuters source:

https://www.reuters.com/article/us-gsk-hiv/gsks-hiv-drug-receives-eu-marketing-nod-idUSKCN1TY0YZ?il=0

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom